Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

NEXT STORY
Ginseng Extracts European Industry to 2026 – Industry Analysis and Forecasts
PREV STORY
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Soricimed Announces Changes to its Board of Directors

MONCTON, New Brunswick, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Soricimed Biopharma Inc. ("Soricimed"), a ...

author_avatar
NASDAQ Market News

ContraFect Appoints Michael Messinger as Chief Financial Officer

YONKERS, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology ...

author_avatar
NASDAQ Market News

Cellaria Forms Strategic Partnership with AMS Biotechnology

CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Cellaria, LLC, a scientific innovator that ...

author_avatar
NASDAQ Market News